Substituted (pyrroloamino)pyridines: Potential agents for the treatment of Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 39, Issue 2, 1996, Pages 582-587

  Davis, Larry ^a   Olsen, Gordon E ^a   Klein, Joseph T ^a   Kapples, Kevin J ^a   Huger, Francis P ^a   Smith, Craig P ^a   Petko, Wayne W ^a   Cornfeldt, Michael ^a   Effland, Richard C ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

N (2 ETHENYL 1H PYRROL 1 YL) N METHYL 4 PYRIDINAMINE MALEATE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; ANIMALS; BIOGENIC AMINES; MICE; PYRIDINES; QUINUCLIDINYL BENZILATE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030035005     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950644v     Document Type: Article

References (22)

1. Bartus, R. T.; Dean, R. L.; Pontecorvo, M. J.; Flicker, C. The cholinergic hypothesis: A historical overview, current perspective and future directions. Ann. N.Y. Acad. Sci. 1985, 444, 332-358.
2. Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-417.
3. Shutske, G. M.; Pierrat, F. A.; Kapples, K. J.; Cornfledt, M. L.; Szewczak, M. R.; Huger, F. P.; Bores, G. M.; Haroutunain, V.; Davis, K. L. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: Synthesis and evaluation as potential Alzheimer's disease therapeutics. J. Med. Chem. 1989, 32, 1805-1813.
4. Hamer, R. R. L.; Helsley, G. C.; Chiang, Y.; Kurys, B. E.; Cornfeldt, M. L.; Szewczak, M. R.; Huger, F. P.; Bores, G. M.; Glamkowski, E. J.; Freed, B. S. Novel 1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indoles: Synthesis and evaluation as potential therapeutics for Alzheimer's Disease. Abstracts of Papers, 201st ACS National Meeting, Atlanta, GA, April 1991, MEDI 74.
5. Santucci, A. C.; Haroutunian, V.; Tsuboyama, G. K.; Kanof, P. D.; Davis, K. L. Therapeutics of Alzheimer's disease for clinical and pre-clinical issues. In Alzheimer's Disease and Related Disorders; Alan R. Liss, Inc.: New York, 1989; pp 1111-1120.
6. Thesleff, S. Aminopyridines and synaptic transmission. Neuroscience 1980, 5, 1413-1419.
7. Klein, J. T.; Davis, L.; Olsen, G. E.; Cornfeldt, M. L.; Huger, F. P.; Smith, C. P.; Petko, W. W.; Wilker, J.; Blitzer, R.; Landau, E.; Haroutunian, V.; Effland, R.C. Synthesis and SAR of HP 749 and related analogs: Potential therapeutic agents for Alzheimer's Disease. Abstracts of Papers, 201st ACS National Meeting, Atlanta, GA, April 1991, MEDI 66.
8. Davis, L.; Kapples, K. J.; Klein, J. T.; Olsen, G. E.; Cornfeldt, M. L.; Huger, F. P.; Smith, C. P.; Petko, W. W.; Wilker, J.; Effland, R. C. Synthesis and SAR of heteroaryl analogs of the 4-pyridinyl-1H-indol-1-amine HP 749: Potential agents for the treatment of Alzheimer's Disease. Ibid. MEDI 104.
9. Klein, J. T.; Davis, L.; Olsen, G. E.; Wong, G. S.; Huger, F. P.; Smith, C. P.; Petko, W. W.; Cornfeldt, M.; Wilker, J. C.; Blitzer, R. D.; Landau, E.; Haroutunian, V.; Martin, L. L.; Effland, R. C. Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipiridine) and related analogs as potential therapeutic agents for Alzheimer's disease. J. Med. Chem. 1996, 39, 570-581.
10. Yamamura, H. I.; Snyder, S. H. Muscarinic cholinergic binding in rat brain. Proc. Nat. Acad. Sci. U.S.A. 1974, 71, 1725-1729.
11. Aronstam, R. S.; Abood, L. G.; Hoss, W. Influence of sulfhydryl reagents and heavy metals on the functional state of the muscarinic acetylcholine receptor in rat brain. Mol. Pharmacol. 1978, 14, 575-586.
12. 3H]QNB displacement by cholinergic agonists and antagonists. Biochem. Pharmacol. 1983, 32, 377.
13. Rush, D. K. Scopolamine amnesia of passive avoidance: A deficit of information acquisition. Behav. Neur. Biol. 1988, 50, 255-274.
14. Benesova, O.; Nahunek, K. Correlation between the experimental data from animal studies and therapeutical effects of antidepressant drugs. Psychopharmacologia 1971, 10, 337-347.
15. U'Prichard, D. C.; Greenberg, D. A.; Snyder, S. H. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol. Pharmacol. 1977, 13, 454-473.
16. Starke, K.; Borowski, E.; Endo, T. Preferential blockade of presynaptic α-adrenoreceptors by yohimbine. Eur. J. Pharmacol. 1975, 34, 385-388.
17. Greenberg, D. A.; U'Prichard, D. C.; Snyder, S. H. Alpha-noradrenergic receptor binding in mammalian brain: Differential labeling of agonist and antagonist states. Life Sci. 1976, 19, 69-76.
18. Horn, A. S.; Coyle, J. T.; Snyder, S. H. Catecholamine uptake by synaptosomes from rat brain. Structure activity relationships for drugs with differential effects in dopamine and norepinephrine neurons. Mol. Pharmacol. 1970, 7, 66-80.
19. Horn, A. S. Structure activity relations for the inhibition of 5HT uptake into rat hypothalamic homogenates by serotonin and tryptamine analogues. J. Neurochem. 1973, 21, 883-888.
20. 2 receptor subtypes. Life Sci. 1983, 32, 3001-3011.
21. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
22. In clinical trials as the hydrochloride salt (besipirdine hydrochloride, HP 749).